Clinical trials: Adverse Effect of Radiation Therapy
Cardiotoxicity
Effect of Trimetazidine on Radiotherapy-induced Heart Damage.
This is a randomized controlled trial. 80 patients with thoracic radiotherapy will be included. Participants will be randomly divided into experimental group or control group.
- Trial name
- NCT04939857
- Testing
- Trimetazidine
- Volunteers
- 80 people
- Sponsor
- Peking University Third Hospital
Lymphoma, Large B-Cell
Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell
All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec.
- Conditions
- Lymphoma, Large B-Cell, Diffuse Large B-Cell
- Trial name
- NCT02916316
- Testing
- R-CHOP with doxorubicin
- Where
- 18 sites in Italy
- Volunteers
- 127 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Breast Cancer, Radio Dermatitis
Photobiomodulation in Radiodermatitis in People With Breast Cancer
Most breast cancer patients undergoing radiotherapy develop radiodermatitis, making it one of the most prevalent adverse events during cancer treatment.
- Trial name
- NCT06990165
- Testing
- Photobiomodulation
- Where
- 2 sites in Brazil
- Volunteers
- 148 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Head and Neck Cancer Survivors, Cancer of the Head and Neck Surviors
Head and Neck Cancer Survivorship Ototoxicity Screening (SOS)
To evaluate the effectiveness, feasibility, acceptability, and appropriateness of an ototoxicity screening protocol among head and neck (H\&N) cancer patients followed in survivorship clinic that received cisplatin-based…
- Trial name
- NCT05789316
- Testing
- Ototoxicity Screening Protocol
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Washington University School of Medicine
Cardiac Disease, Cancer
Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)
Antineoplastic and immunomodulating agents may lead to various cardio-vascular adverse reactions. This study investigates reports of cardio-vascular toxicities for treatment including Anatomical Therapeutic Chemical (ATC)…
- Trial name
- EROCA (NCT03530215)
- Testing
- Antineoplastic and Immunomodulating Agents
- Where
- France
- Volunteers
- 500,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Breast Cancer, Cardiotoxicity
Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab
The aim of the study is to analyze the protective impact on the cardiac damage of beta blockers and ACE inhibitors for breast cancer patients treated with anthracyclines-based chemotherapy with or without trastuzumab.
- Trial name
- SAFE (NCT02236806)
- Testing
- Bisoprolol, Ramipril
- Where
- Italy
- Volunteers
- 262 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Cardiotoxicity, Breast Cancer
Early Detection of Cardiac Damage With CMR in Women With Breast Cancer
With this study the investigators will assess early cardiac damage by means of Global Longitudinal Strain (GLS) in newly diagnosed breast cancer (BC) patients treated with anthracycline-based chemotherapy, and to investigate…
- Conditions
- Cardiotoxicity, Breast Cancer, Chemotherapy Induced Systolic Dysfunction
- Trial name
- EARLY-CATCH (NCT04046315)
- Testing
- CMR
- Where
- Netherlands
- Volunteers
- 55 people
- Sponsor
- Radboud University Medical Center
Myotoxicity
Effects of Postoperative Analgesic Modalities on Plasma Creatine Phosphokinase(CPK) Levels After Knee Artroplasty
Regional anesthesia and analgesia technics are widely and securely used during orthopedic surgery. Interfascial plane blocks are the latest used ones for analgesia.
- Trial name
- NCT05505890
- Testing
- suprainguinal fascia iliaca block
- Where
- Turkey (Türkiye)
- Volunteers
- 82 people
- Sponsor
- Samsun University
Artificial Intelligent, Cardiotoxicity
Smart Home Care of Cloud Base ECG on the Cardiotoxicity Prevention on the Cancer Patients.
Thoracic malignancy is the most commonly diagnosed cancer worldwide.1,2 The incidence of thoracic malignancy has decreased in North America, but not in Asia, where it continues to show an increasing trend.
- Conditions
- Artificial Intelligent, Cardiotoxicity, Cardiac Monitor, Cancer Treatment
- Trial name
- AI (NCT04885088)
- Testing
- Wisdom bracelet
- Volunteers
- 400 people
- Sponsor
- Ju-Chi Liu
Cardiotoxicity, Acute Myeloid Leukemia in Children
Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia
Prevention and early detection of chemotherapy-induced cardiotoxicity in children with bone tumors and Acute Myeloid Leukemia by giving capoten
- Conditions
- Cardiotoxicity, Acute Myeloid Leukemia in Children, Bone Tumor
- Trial name
- NCT03389724
- Testing
- Capoten®
- Where
- Egypt
- Volunteers
- 245 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Breast Cancer, Radiation Fibrosis
IH636 Grape Seed Extract in Treating Hardening of Breast Tissue in Women Who Have Undergone Radiation Therapy for Early Breast Cancer
RATIONALE: IH636 grape seed extract may lessen hardening of breast tissue caused by radiation therapy and may help patients live more comfortably.
- Trial name
- NCT00041223
- Testing
- IH636 grape seed proanthocyanidin extract
- Where
- United Kingdom
- Sponsor
- Royal Marsden NHS Foundation Trust
Cancer
Detection of Chemotherapy Induced Cardiotoxicity
To identify patients that are at risk of heart damage after receiving chemotherapy (adriamycin).
- Trial name
- NCT00636844
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- George Washington University
Cardiomyopathy, Cardiac Failure
Cardiac Assessment of Patients With Hip Implants
PRIMARY OBJECTIVE To establish the effect of metal ion release from metal hip implants on cardiac function STUDY OUTCOME MEASURES To assess the effect of metal ions from hip implants on cardiac function as measured by Cardiac…
- Trial name
- NCT02331264
- Testing
- Exposure to metal debris
- Where
- 2 sites in United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Royal National Orthopaedic Hospital NHS Trust
Ototoxic Hearing Loss, Ototoxic Hearing Loss, Bilateral
Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity
The purpose of this study is to assess the efficacity of N-acetylcystein against Cisplatin-induced ototoxicity.
- Conditions
- Ototoxic Hearing Loss, Ototoxic Hearing Loss, Bilateral, Ototoxicity, Tinnitus
- Trial name
- NCT04226456
- Testing
- N-acetyl cysteine
- Where
- Belgium
- Volunteers
- 19 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Erectile Dysfunction Following Radiation Therapy, Phosphodiesterase Inhibitor Adverse Reaction
A Randomized Trial to Evaluate Efficacy and Safety of Intracavernosal Injection of Platelet-Rich Plasma Versus Phosphodiesterase Type-5 Inhibitors for Treatment of Erectile Dysfunction.
The aim of this study is to evaluate the efficacy and safety of intracavernosal injection of PRP in patients with moderate to severe ED.
- Conditions
- Erectile Dysfunction Following Radiation Therapy, Phosphodiesterase Inhibitor Adverse Reaction, Platelet- Rich Plasma (PRP)
- Trial name
- NCT05787769
- Testing
- P shot arm ( Autologous Platelet Rich Plasma), PDE5i arm
- Where
- Egypt
- Volunteers
- 96 people
- Sponsor
- Mansoura University
Wilms Tumor, Neuroblastoma
Pharmacokinetic Study of Doxorubicin in Children With Cancer
Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity .
- Conditions
- Wilms Tumor, Neuroblastoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia
- Trial name
- Doxo (NCT01095926)
- Testing
- doxorubicin
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- University Hospital Muenster
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation…
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Trial name
- NCT00003583
- Testing
- amifostine trihydrate, cisplatin, etoposide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Adverse Radiation Effects, Radiation Necrosis
Microbiome Determinants of Adverse Effects of Stereotactic Radiosurgery
This prospective observational study will investigate the relationship between the gut microbiome and adverse effects following stereotactic radiosurgery (SRS).
- Trial name
- MICRO-ARE-SRS (NCT07767981)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Chicago
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
- Trial name
- START (NCT06214195)
- Testing
- Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Zhejiang Cancer Hospital
Chronic Pelvic Pain Syndrome (CPPS), Radiation-Induced Disorder
Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Cancer Treatment
Gynecological cancers, including those affecting the ovaries, uterus, and cervix, represent a significant health burden for women.
- Conditions
- Chronic Pelvic Pain Syndrome (CPPS), Radiation-Induced Disorder, Radiotherapy Side Effects, Side Effect of Chemotherapy
- Trial name
- OzoGynEpigen (NCT06816095)
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Bernardino Clavo, MD, PhD